Compare AbbVie Inc (ABBV) vs Expensify Inc (EXFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Expensify Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Expensify Inc trades at $1.87 (market cap $179.86M). The key difference: AbbVie Inc is far larger — about 2501.4× Expensify Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| ABBV | EXFY | |
|---|---|---|
Market Cap | $449.91B | $179.86M |
Sector | Health | Technology |
52-Week High | $261.07 | $2.51 |
52-Week Low | $184.85 | $0.75 |
Enterprise Value | $513.38B | $118.89M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Expensify (EXFY) trades at $1.71, up 0.59% with a bullish technical signal from moving averages. The company maintains strong revenue around $142M but continues to report net losses, with a negative net income margin of -14.68%. Recent developments include AI product expansions and a $25M stock buyback program. Analyst sentiment is mixed with a 44% buy rating, while technical indicators show RSI levels suggesting potential overbought conditions near-term.
The outlook remains challenging with persistent profitability issues despite stable revenue. Investment opportunity exists in the company's AI initiatives and market positioning, but risks include ongoing losses, competitive pressure, and execution challenges. The stock's high P/E ratio of 258.82 reflects growth expectations that must materialize to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
